治疗丙肝药物索非布韦的研究进展

Research progress in sofosbuvir for the treatment of hepatitis C

索非布韦（sofosbuvir，SOF）是全球首个无需同时使用干扰素即可实现全口服治疗丙肝的药物，为丙型肝炎病毒（HCV）特异性NS5B聚合酶的核苷抑制剂。临床试验表明，SOF和利巴韦林二联全口服方案可用于治疗基因2型、3型HCV的感染，用药12周总体持续病毒学应答率（SVR）为50％～78％。SOF联合聚乙二醇干扰素和利巴韦林可用于基因1型和4型HCV的感染，用药12周的SVR达90％。SOF因其服用简便，治愈率高，不良反应发生率低等特点，使其极有可能成为“重磅炸弹”型药物。

Sofosbuvir （SOF） ,a novel hepatitis C virus （HCV） nucleoside analog NSSB polymerase inhibitor,might be the first drug on the globe that achieved an INF free all oral regimen in the treatment of chronic HCV infection. Clinical trials indi- cated that SOF combined with ribavirin could be used for the treatment of chronic hepatitis C（CHC） patients with genotypes 2 and 3 infections. Twelve weeks after medication, overall sustained virological response （SVR） was 50%-78%. SOF combined with peginterferon （PEG-IFN） and ribavirin could be used for the treatment of CHC patients with genotypes 1 and 4 infections, and 12 weeks after medication,SVR was as high as 90z5. Having the features of easy administration,high cure rate and low rate of adverse reactions,SOF will be likely to be the most potent ＂blockbuster＂ type drug for the treatment of the disease.